Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2015

Purification of Recombinant Δ Np63 α and Characterization of
Peptide Binding
Amal Abdulah Albati
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Molecular Biology Commons

Repository Citation
Albati, Amal Abdulah, "Purification of Recombinant Δ Np63 α and Characterization of Peptide Binding"
(2015). Browse all Theses and Dissertations. 1608.
https://corescholar.libraries.wright.edu/etd_all/1608

This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

PURIFICATION OF RECOMBINANT NP63AND
CHARACTERIZATION OF PEPTIDE BINDING

A thesis submitted in partial fulfillment
of the requirements for the degree
of Master of Science

By

AMAL ABDULAH ALBATI
B.S., King Saud University, 2008

2015
Wright State University

WRIGHT STATE UNIVERSITY
GRADUATE SCHOOL
August 19, 2015
I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY
SUPERVISION BY Amal Abdulah Albati ENTITLED Purification of Recombinant
NP63and Characterization of Peptide Binding BE ACCEPTED IN PARTIAL
FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science
Madhavi P. Kadakia, Ph.D.
Thesis Director

Madhavi P. Kadakia, Ph.D.
Chair, Department of Biochemistry and
molecular biology
Committee on
Final Examination

Madhavi P. Kadakia, Ph.D.

Yong-jie Xu, Ph.D.

Michael Markey, Ph.D.

Robert E. W. Fyffe, Ph.D.
Vice President for Research and
Dean of the Graduate School

ABSTRACT

Albati, Amal Abdulah. M.S. Department of Biochemistry and Molecular Biology, Wright
State University, 2015. Purification of Recombinant Np63and Characterization of
Peptide Binding
Np63, the primary p63 isoform of the p53 transcription factor family, is a protooncogene implicated in non-melanoma skin cancers. Expressed in the basal layer of the
epidermis, Np63 promotes cell survival and proliferation. Inhibition of this protein
could potentially be beneficial in non-melanoma skin cancer patients.
The first goal of this project was the purification of recombinant Np63 in
Escherichia Coli. Recombinant Np63 was expressed as GST-Np63 followed by GST
cleavage using GST trap affinity column chromatography yielding pure Np63 The
second objective of this project was to test the binding capabilities of peptides previously
identified by phage display to Np63. Six 12-mer peptides were previously identified by
phage display using filamentous phage M13 followed by biopanning and amplification of
target bound peptides. The amplified pools were sequenced and studied. In this study, the
identified peptides were linked to biotin, the affinity and specificity of these peptides was
evaluated using two different methods, streptavidin Dynabeads and ELISA. Through these
methods, the biotinylated peptide P5 was found to be the most specific peptide to bind
Np63. Future results utilizing these techniques may reveal promising therapeutic agents
for the treatment of non-melanoma skin cancer.
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I.

INTRODUCTION

A. P63 AND ITS ROLE IN EPIDERMAL DEVELOPMENT
The skin protects the body from ultraviolet radiation, microorganisms and
dehydration (Vanbokhoven et al, 2011). The major compartments in the skin are the dermis
and the epidermis. The latter is multilayered and is important to form the skin barrier (Candi
et al, 2006). Symmetric division in the basal layer of the epidermis generates new
keratinocytes. Some keratinocytes divide asymmetrically and separate from the basal layer
to undergo differentiation and generate cornified cells. Disruption of this controlled process
causes pathological conditions such as inflammation, disruption of the skin barrier and
cancer (Vanbokhoven et al, 2011). The p63 transcription factor, a p53 family member,
plays important roles in epidermal morphogenesis (Candi et al, 2006; Pellegrini et al, 2001;
Perez & Pietenpol, 2007). Studies have shown the importance of the p63 in development,
apoptosis and tumorigenesis (Caserta et al, 2006; Dotsch et al, 2010; Schavolt & Pietenpol,
2007; Trink et al, 2007). Mutations in p63 lead to limb and skin defects in humans. p63
knock out mice show several abnormalities such as truncated limbs, absence of hair, teeth,
nails, and neonatal death due to dehydration (Candi et al, 2006; Caserta et al, 2006; Dotsch
et al, 2010; Marinari et al, 2009; Restelli et al, 2015)
The human p63 gene is located on chromosome 3q28 and contains 16 exons. It is
structurally homologous to the p53 tumor suppressor gene, but does not function as a
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classical tumor suppressor gene. The homology between p53 and p63 is mainly present in
a shared N-terminal transactivation domain (TA), a C-terminal oligomerization domain
(OD) and a central DNA binding domain. p63 is expressed in multiple isoforms which
perform different functions, thus resulting in a complex contribution to tumorigensis (Moll
& Slade, 2004). As shown in Figure 1, all p63 isoforms contain a DNA-binding domain
and an oligomerziation domain. p63 isoforms either contain a full-length transactivation
(TA) domain or a truncated N-terminal transactivation version (denoted N). The
expression of p63 is initiated from two different transcriptional start sites denoted P1 and
P2 which generate two different p63 isoforms: TAp63 isoforms which includes a fulllength N-terminal transactivation domain (TA) and Np63 versions which contains a
short unique N-terminal domain (Caserta et al, 2006; Dotsch et al, 2010; Marinari et al,
2009; Moll & Slade, 2004; Vanbokhoven et al, 2011; Yang et al, 1998). Full length or
truncated (,) isoforms are generated by alternative 3′-end splicing (Courtois et al, 2004;
Dotsch et al, 2010; Yang et al, 1998). -isoforms contain a sterile alpha motif (SAM)
domain which mediates protein-protein interactions and a trans-inhibitory domain (TI)
which blocks the transactivation by covering a few residues on the N-terminal TA domain
(Caserta et al, 2006; Dotsch et al, 2010; Marinari et al, 2009; Moll & Slade, 2004;
Vanbokhoven et al, 2011; Yang et al, 1998). Np63 is primarily expressed in the basal
layer and downregulated in keratinocytes (Guo & Mills, 2007; Koster et al, 2004; Moll &
Slade, 2004; Vanbokhoven et al, 2011). Both TAp63 and Np63 isoforms are conserved
in human and mice.
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Figure 1: Gene architecture of p63 isoforms. Alternative promotors (P1, P2) and
alternative splicing (, , ) are indicated. All p63 isoforms consist of TA, DBD and OD
domains. The  isoforms contain SAM and TI domains. Alternative promotor usage P1
and P2 gives rise to transactivation isoform (TA) and N-terminal truncated (N) isoform
respectively.
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B. P63 AND ITS ROLE IN CANCER
p63 is involved in the regulation of development, proliferation, tissue regeneration,
morphogenesis, cell adhesion and cell signaling (Pellegrini et al, 2001; Perez & Pietenpol,
2007; Vanbokhoven et al, 2011). The TA and N p63 isoforms have opposing roles in
blocking or enhancing proliferation, and inducing or blocking cell death, but the
mechanism by which these isoforms elicit their various functions is not currently fully
understood.
p63 function is frequently lost or amplified in human cancer (Flores, 2007; Leonard
et al, 2011; Trink et al, 2007). The p63 locus is frequently amplified in squamous cell
carcinoma (Deyoung & Ellisen, 2007; Guo & Mills, 2007). Np63, the major isoform
expressed in the suprabasal cells of the epidermis (Carroll et al, 2006; Moll & Slade, 2004;
Pellegrini et al, 2001), is found to be amplified in various squamous cell carcinomas
including head, neck and lung (Crook et al, 2000; Flores, 2007; Trink et al, 2007). Further,
studies have shown that Np63 inactivates p53. Np63 promotes cell proliferation by
downregulation of p53 target gene p21 (Deyoung & Ellisen, 2007; Flores, 2007; Trink et
al, 2007). It was also shown that Np63 preventing cell apoptosis through binding to the
p53 response elements in p21 and 14-3-3σ (Westfall et al, 2003).
C. PHAGE DISPLAY
Phage display is a laboratory technology first described by George P. Smith in 1985
(Zwick et al, 1998) which is used to determine the interaction partners of a given protein.
It is a potent technique that identifies new functions for peptides, and hence it is an
important tool used in drug discovery. In this approach, a library of phages is generated
which express a diversity of exogenous peptides. The filamentous phage M13 is the most
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used bacteriophage to produce random display peptides library. The library is then utilized
to identify specific peptide ligands which bind a specific target (Barbas, 1993; Pande et al,
2010; Smith & Petrenko, 1997). The foreign DNA fragment that encodes different peptides
is inserted into the filamentous phage genome. Then, the expressed peptides are fused on
the surface of the coat proteins of the phage.
Screening for the specific target binding peptides is done by a process called
biopanning.

Biopaning is performed by exposing enriched phage clones to the

immobilized desired target followed by washing off unbound peptides. Next, the target
bound peptides are eluted and amplified followed by repeating biopanning process three to
six times. Then, each clone is characterized by DNA sequence to identify target bound
peptides (Figure 2). Phage display has been used to identify new protein-protein, proteinpeptide, and protein-DNA interactions (Azzazy & Highsmith, 2002; Pande et al, 2010;
Sergeeva et al, 2006; Smith & Petrenko, 1997; Takakusagi et al, 2010; Takami et al, 2011).
Phage display has been applied in different studies such as identification of
peptides, antibodies, and vaccines (Dai et al, 2014; Kang et al, 2013; Ladner et al, 2004;
Loi et al, 2013; Portefaix et al, 2002; Smith & Petrenko, 1997; Takami et al, 2011;
Uchiyama et al, 2005; Wang et al, 2013; Winter et al, 1994).Using phage display, it is
possible to identify peptides with high affinity and specificity to a target protein. These
peptides can be used as drug candidate to inhibit the activity of target protein (Ladner et al,
2004). In our laboratory, it was used to identify six peptides that bind to Np63. In this
study, two methods were used to determine if the identified peptides have the capacity to
bind Np63 using biotinylated peptides bound to either streptavidin Dynabeads pull
down or 96-well streptavidin-based ELISA assays.
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Figure 2: Schematic showing steps in screening a phage library to select p63 specific
peptides by biopanning. The biopanning process starts with target immobilization. The
unbound target is then washed off followed by elution of target bound phages. The eluted
phages are amplified and the biopanning process is repeated three to four times under
stringent conditions following which the phages are analyzed by DNA sequencing to
identify the sequence of the target binding peptides.
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D. RATIONALE AND SPECIFIC AIMS
Np63 isoform of p63, is overexpressed in many cancers, and has oncogenic
activity due to its ability to induce cell proliferation and inhibit cell apoptosis (Ram Kumar
et al, 2014). This dissertation describes the identification of novel peptides which bind to
Np63 by phage display technology. Phage display technology has been used to show
that peptides which bind specifically to the oncogenic peptide MDM2 can be used to target
its function and prevent its binding to p53 (Bottger et al, 1996). Another phage display
study demonstrated the ability of peptide P12 to bind to fibroblast growth factor (FGF8b),
and interrupt binding to its receptor (Wang et al, 2013).
In this dissertation research, we completed two specific aims. First, recombinant
Np63 was produced in Escherichia coli bacteria and purified using column
chromatography. Second, the recombinant protein was used to evaluate the binding of
peptides P1 through P6 identified by phage display to both recombinant and transfected
Np63 in vitro.
The research presented herein suggests that chosen peptides P3, P5 and P6 may be
used to target endogenous Np63 and modulate its oncogenic function. Further testing
is needed to determine the therapeutic potential of these peptides in treating squamous cell
carcinoma and other p63-mediated malignancies.
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II.

MATERIAL AND METHODS

A. Recombinant ∆Np63α preparation
Np63 cloned into the pGEX vector was a generous gift from Dr. Basu (Restelli et al,
2015). Np63 was expressed as a GST tagged-Np63 in Rosetta Escherichia coli and
grown in Difco LB Broth, Miller (Luria-Bertin) in the presence of 100 g/ml ampicillin,
25 g/ml chloramphenicol and 1mM glucose. A fresh 100 ml starter culture was incubated
overnight at 37oC at a shaking speed of 250 rpm and used to inoculate four large scale 500
ml cultures. When the cultures reached an optical density of 1 at 600nm (O.D₆₀₀), 1 OD
equivalent of uninduced culture was collected and pelleted for induction of recombinant
GSTNp63 by adding 1mM isopropyl β- D -1thiogalactopyranoside (IPTG) (Life
technologies, cat # 15529-019). The cultures were incubated for 3.5 hours following
induction and collected by centrifugation at 5,000 rpm for 10 minutes. Another 1 OD
equivalent of induced cells was collected following centrifugation at 15,000 rpm for 5
minutes. Phenylmethanesulfonyl fluoride (PMSF) (sigma Product # P7626) was added to
the pellet at a final concentration of 0.5mM and the cells were frozen at -80oC until the day
of purification (Figure 3A). The remaining cells were frozen as cell pellets for additional
large scale preparations.
Small scale test for GST-Np63 induction was performed as follows: 1 OD equivalent
pellets from both uninduced and induced samples were resuspended in 100 l 1X L&C
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Figure 3: Np63 purification workflow. A) A 100 ml starter culture was incubated
overnight at 37ºC. The next day, the 100 ml starter culture was inoculated into a two liter
culture and incubated at 37ºC until the optical density reached 1. A 1OD equivalent aliquot
was collected and the rest of the culture was induced by IPTG and incubated for additional
3.5 hours. A 1 OD equivalent sample of induced cell aliquot was collected and the rest was
spun and frozen at -80ºC. B) Expression of GSTNp63 in 1 OD equivalent of uinduced
and induced cells. Both culture samples were lysed in 1X L&C lysis buffer followed by
sonication. A 20 microliter aliquot of whole cell extract was collected and the rest was spun
for 5 minutes at 15,000 rpm speed. Supernatants (soluble fraction) were collected and the
pellet (insoluble fraction) was resuspended using 1X L&C. 20 l induced and uninduced
samples were run on an SDS gel and stain with Coomassie Blue staining. C) After
confirmation of expression of GST-Np63, the large scale frozen pellet was resuspended
in 1X L&C and homogenized three times using an EmulsiFlex-C3 cell homogenizer. The
cell lysate was then clarified at 10,500 rpm, filtered and purified by GST trap affinity
chromatography.
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lysis buffer (2X L&C: 40mM Tris pH 8.0, 600mM NaCl, 20% glycerol). The resuspended
cell pellets were sonicated three times for 15 seconds each and an aliquot of the whole cell
extract was collected from both induced and uninduced samples. Next, the samples were
centrifuged at 15,000 rpm for 5 minutes and the supernatant was collected as the soluble
fraction. The insoluble fraction (pellet) was resuspended in 100 l of 1XL&C lysis buffer.
20 l of whole cell extract, soluble and insoluble fractions from uninduced and induced
conditions were run on 10% SDS gel after in 1X loading dye. GST-Np63 expression
was detected following staining the gel with instant blue stain (Expedeon, Product#
140904001) (Figure 3B) Following confirmation of induction on a small scale, frozen cell
pellets from large scale preparations were thawed and resuspended in 100 ml 1X L&C
buffer containing Protease Inhibitors Cocktail (PIC), homogenized three times using a
Emulsiflex cell homogenizer (Avestin, Inc.) for 25 minutes, and spin-clarified by
centrifuging the lysate at 10,500 rpm at 4oC for 30 minutes. The supernatant then was
filtered through a 0.45 μm pore PES Filter (Figure 3C).
Recombinant GST-Np63 protein was purified from contaminating proteins using
GSTrap FF affinity columns (GE health care life science, product code 17-5130-01). The
principle of column chromatography is shown in Figure 4A and 4B. In preparation for
affinity purification, capillaries were rinsed at maximum speed with dH₂O and washed
with 1X L&C buffer. A 1ml column was then installed and equilibrated with 1X L&C
buffer at a flow rate of 1 ml/min. Next, the supernatant was loaded at a flow rate of 0.5
ml/min and washed with 1X L&C overnight at flow rate of 0.5ml/min at 4oC. The column
was then equilibrated in PreScission buffer (50mM Tris HCl, 150mM NaCl, 1mM EDTA
1mM DTT, pH 8.0), followed by equilibration in PreScission protease dissolved in
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Figure 4: GST-Np63 purification schematic. A) In column digestion: GST-Np63
was loaded onto a GST affinity column followed by 16 hours incubation with PreScission
protease, resulting in pure Np63. B) In vitro digestion of GSTNp63: GSTNp63
was loaded to the column following by elution of GST-Np63 using reduced glutathione.
This step was followed by mixing GST-Np63 and PreScission enzyme in an overnight
incubation.

16

PreScission buffer and incubation for 16 hours. The bound GST tagged Np63 was
collected manually by injecting 1 ml of 10mM reduced glutathione (Sigma-aldrich,
Product# G4251). GST tagged Np63 was further concentrated and size selected by
spinning the protein in a 50KD cutoff Amicon filter unit using a Sorvall Legend T/RT
centrifuge. In vitro digestion of GST tagged Np63 was performed with PreScission
Protease in 1.7 ml Eppendorf tubes by incubating overnight (approximately 16 hours) at
4oC. Next, a second round of size selection was performed in a 50KD cutoff Amicon filter
unit using a Sorvall Legend T/RT centrifuge. Purity of the recombinant Np63 was
evaluated on a 10% SDS gel stained with Instant blue stain (Expedeon, Inc., catalog #
ISB1L).

B. Quantitation of recombinant Np63
Protein concentration was determined by comparing samples against known
concentrations of 1mg/ml bovine serum albumin solution ranging from 0.1 g to 2g per
lane. Both standard BSA and diluted Np63 (5 l Np63 diluted in 13 l of sterile
distilled) were mixed with 2 µl 10X loading dye (0.5M DTT, 10% SDS, 0.5M Tris pH=8,
50% glycerol, 0.2% bromophenol blue). The sample were heated at 97ºC for 10 minutes
and then run on a 10X SDS-PAGE gel. Purified Np63 protein was detected by staining
the gel with Coomassie blue stain (0.1% Coomassie brilliant blue, 10% acetic acid, 50%
of 95% ethanol, 40% H2O) at room temperature for 1 hour. Coomassie destaining solution
(7.5% acetic acid, 20% methanol, 72.5%H2O) was added to the gel and incubated from 15
minutes to overnight at 4ºC as needed to visualize the protein bands. Np63 concentration
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was measured by densitometry using Multi Gauge software and plotting against a standard
curve generated by the density of BSA standards.
C. Western blots
Purified Np63 was run on a 10 % SDS-PAGE followed by transfer onto
Immobilon-P PVDF membrane (Millipore Corporation, Billerica, MA) using transfer
buffer (25mM Tris, 192mM glycine, 20% methanol and PH 8.3) at 0.35A for 60 minutes
using transblot system (Bio-Rad). The blot was then blocked using 5% nonfat dry milk
made in 1X Tris-Tween 20 buffer saline (1X TTBS: 50mM TRIS-Cl, 150mM NaCl, pH
7.6) for 1h at room temperature. Np63 was detected using the following anti-p63
antibodies: polyclonal H-129 (1:1000), monoclonal 4A4 (1:4000) and monoclonal N2C1
(1:2000) (Santa Cruz biotechnology, Inc.) followed by incubation in the respective
secondary antibody (1:2500 dilution of anti-mouse-HRP catalog # W4011 or anti-rabbit
IgG catalog # W402B-HRP, Promega Corp.). Membranes were washed three times with
1X TTBS for 15 minutes each and then submerged in Super-signal West Pico
Chemiluminescent substrate (Pierce, Rockford, IL) for 1 minute. Chemiluminescence was
quantified using the Fuji Film LAS 4000 image reader (Fuji Medical System USA, Inc.).
D. Synthesis of biotinylated Peptides
Six 12-mer peptides (Table 1) were identified by a previous lab member (Dr.
Pavyluk) using a Ph.D.-12 phage display peptides library kit (New England Biolabs,
Beverly, MA, USA). These sequences were synthesized by Genscript USA, Inc. as biotin
conjugated peptides. Each peptide vial (0.5mg pellet) was spun and reconstituted in 5000
μl Sterile PBS/0.01% Tween 20. The concentration of peptides used in the assay was 50
pmol.

18

Table 1: Sequence and molecular weights of biotin conjugated peptides identified by
phage display.

Phage

Amino acids sequence

Mwt (Dalton)

P1

SLYHQYVTVMMHGG(lys){biotin}

1977.34

P2

HVVKQAMSNNMMGG(lys){biotin}

1858.25

P3

SSAHWRHFNWNLGG(lys){biotin}

2023.25

P4

VIAMDNYNGTTRGG(lys){biotin}

1823.07

P5

KPFHHHQMHLANGG(lys){biotin}

1965.28

P6

HHYNWNLPWLMSGG(lys){biotin}

2066.38
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E. Binding of Np63 to Np63 specific peptides identified by phage display using
Streptavidin conjugated Dynabeads
Streptavidin M-280, M-270, Myone C1 and Myone T1 Dynabeads (Life Technologies,
trial kit catalog # 65801D) were tested for use in binding studies. The streptavidin
Dynabeads were washed with 0.01% PBS / Tween 20 followed by incubation with 50 and
100 pmol biotinylated peptides for 4 hours. Next, the beads were captured using DynaMag
magnet separation (Life Technologies, Inc.) followed by washing 3 times with 0.01% PBS
/ Tween 20. The beads were then resuspended again with 0.01% PBS / Tween 20 buffer,
incubated with 14.38 pmol Np63 protein and incubated overnight at 4oC. The beads
were collected using magnetic capture (as before), resuspended and washed with 0.01%
PBS / Tween 20 buffer in three 10-minute washes. The beads were then resuspended and
run onto 10 % SDS-PAGE gel and immunoblotted with a polyclonal H-129 p63-specific
antibody as previously described (1:1000).

F. Enzyme-linked immunosorbent assay (ELISA)
The 6 different peptides (200 pmol) dissolved in Tris-buffered saline washing buffer
(25mM Tris, 150mM NaCl, 0.1% BSA, 0.05% Tween 20, pH 7.2) were coated onto
Streptavidin High Binding Capacity Coated 96-well Plate (Pierce, catalog #15500) and
incubated overnight at 4oC. Excess unbound peptides were removed by washing the wells
3 times. Different concentrations of Np63 were then added to each well in a total volume
of 100μl of washing buffer. After incubation for 2 hours, the wells were washed three times
with washing buffer. The bound Np63 was then incubated with Np63 specific
antibodies, H-129 (1:1000), or N2C1 (1:2000) for 1 hour followed by three washes and
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incubation for an additional 1 hour with anti-rabbit IgG conjugated with horseradish
peroxidase (1:2500) (Promega Corporation, catalog # W4011). After three washes, 100l
of substrate 3, 3´, 5, 5´- tetramethyl-benzidine (1-Step Ultra TMP-ELISA, Thermo
Scientific, catalog # 34028) was added per well and the plate was incubated for 20 minutes.
The reaction was terminated by adding 100l / well of 2M H₂SO₄. The absorbance was
measured at 450nm using a Safire monochromator microplate reader (Tecan Group Ltd.).
Biotinylated peptides and GST were used as negative controls in the experiment.

G. Transfections
Human lung carcinoma H1299 cells were seeded at 3 x 105 per well. Next day, cells
were transfected overnight with increasing concentrations of Np63 expression plasmid
or empty vector control using Lipofectamine 2000 (Life Technologies, Inc., catalog #
11668019). At 24h post-transfection, cells were washed with 1X PBS, harvested with a
25% trypsin-ETDA solution and transferred and pelleted in Eppendorf tubes. Whole cell
extracts were made by resuspending cell pellets in 100 μL of phosphate inhibitor buffer
(PhIB) (50mM Tris pH 8, 120mM NaCl, 5mM EGTA, 1mM EDTA, 5mM sodium
pyrophosphate decahydrate, 10mM NaF, 30mM para-nitro phenyl phosphate, 1mM
benzamidine, 0.1%NP-40, and 1X sodium vanadate) plus 1% protease inhibitor cocktail
(PIC) (Sigma-Aldrich Co.). Samples were vortexed in the PhIB and PIC every ten minutes
for a total of 40 minutes while on ice and then centrifuged for 5 min at 14,000 rpm at 4°C.
Protein concentration was determined using Pierce BCA reagent (Life Technologies, Inc.,
catalog # 23228) in a 96-well plate format. BCA standard curve was generated using
Bovine Serum Albumin (BSA) in PBS at concentrations ranging from 1 g to 13 g. To
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determine sample concentrations, 1 l of sample was added to 99 l of sterile distilled
water for use in the BCA protein assay. To each well (standard or sample) 100l of BCA
reagent was added and the plate was incubated at 37°C for 15 minutes. Absorbance was
measured using a Synergy H1 microplate spectrophotometer (BioTek Instruments, Inc.) at
562 nm and the protein concentration was calculated using a BSA standard curve.
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III.

RESULTS

A. Full length Np63 protein purification:
i. Development of recombinant methodology to express Np63 protein:
Recombinant Np63 protein was successfully purified using a GST-tag based
purification strategy. The initial (pilot) GST-Np63 purification was performed using
uninduced and induced 1OD equivalent of bacteria collected from two liter culture induced
using a 3.5 hour incubation with IPTG. Assessment of GST-Np63 expression by
Coomassie Blue stained 10% SDS-PAGE gel indicated induction of a 100KD band
corresponding to the expected molecular weight for GST-Np63 (Figure 5).
ii. Large scale purification of Np63: After GST-Np63 expression was
confirmed in the pilot purification, we proceeded to purify Np63 from a two liter cell
culture. GST-trap affinity chromatography was utilized to capture the GST-Np63 fusion
protein and subsequently cleave the GST tag. In order to obtain pure Np63 protein,
elution was performed using PreScission protease as shown in the first two lanes (Figure
6). The third and fourth lanes demonstrate abundant levels of GST-Np63 and Np63
were eluted with reduced glutathione.

This suffested that in-column digestion with

Precission protease did not effectively elute untagged Np63. GST-Np63 was also
subjected to in vitro digestion with PreScission protease by mixing the GST-Np63 with
the appropriate amount of PreScission protease. The cleavage of GST was confirmed by
Coomassie Blue staining which was indicated by an increase in the 73kDa protein and loss
of the 100kDa GST-Np63 band (Figure 7).
23

GST-Np63
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Figure 5 : Coomassie Blue staining gel demonstrates IPTG induction of recombinant
GSTNp63 (No IPTG or IPTG). Arrow indicates increased levels of GST-Np63
was observed in the whole cell extracts and in the insoluble fraction, but not in the soluble
fraction of IPTG induced sample.
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Figure 6: Large scale purification of GST-Np63 followed by digestion with
PreScission protease to cleave GST. Two different aliquots of preparations eluted by
PreScission protease followed by reduced glutathione were loaded onto the gel. The
majority of Np63 was found in the fraction eluted by reduced glutathione.
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Figure 7: An aliquot of GST- Np63 was subjected to in vitro digestion by
PreScission protease for GST cleavage. Digested proteins were loaded onto an SDSPAGE gel and stained with instant Coomassie Blue stain indicate efficient cleavage of GST
(first 2 lanes). GST-Np63 was used as a control.
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Size selection performed using a 50 kDa cutoff Amicon filter successfully removed
non-specific contamination from the crude recombinantNp63 sample. As shown in
Figure 8, size-selection removed most of the non-specific bands from the crude Np63
and GST-Np63.
B. Quantitation of Np63:
Recombinant Np63 was quantified by densitometry against a standard curve of
Bovine Serum Albumin (BSA). BSA standards from 0.1 g to 2 g were run alongside
Np63and the gel was stained with instant blue stain and analyzed using Multi-Gauge
(Figure 9A). The concentration of Np63 was calculated using the BSA standard curve
(Figure 9B) and found to be 116 ng / l.
C. Detection of the lower band in recombinant Np63 sample:
In order to evaluate the possibility that the lower band in Figure 8 not a breakdown
product of p63 or a heat-shock protein, we performed the following experiments: First, the
recombinant Np63 sample was treated with ATP during column purification to remove
the band if it was a heat shock protein. (ATP is known to cause conformation changes in
heat shock proteins.) Figure 10 showed that migration of the lower band was not affected
by the addition of ATP, thus indicating that is was likely not a heat shock protein.
Immunoblot analysis was performed using three independent Np63 specific
antibodies (4A4, N2C1, H-129). The lower band was not detected by these antibodies, thus
indicating that the lower band was not a degradation product of Np63 (Figure 11).
Finally, an anti-GST antibody was utilized to determine if the lower band was GST.
Western blot analysis showed that lower band was detected as GST (Figure 11B). Mass
spectrometry confirmed that lower band was GST (data not shown).
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Figure 8: Size selection performed on Np63to remove nonspecific contamination.
Following the GST trap column chromatography, size selection was performed using a 50
KD cut-off Amicon filter to discard bands lower than 50 KD.
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A)

B)
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Figure 9: Quantitation of Np63 using a bovine serum albumin standard. A)
Increasing amount of BSA standard (0.5g-2g) and 5 l of recombinant Np63 were
subjected to SDS-PAGE. B) Band density of standard BSA dilutions were used to quantify
the amount recombinant Np63 concentration.
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Figure 10: ATP treatment performed during the column affinity purification of
Np63. The sample was applied to the column, equilibrated in wash buffer, and ATP
was applied followed by sample elution. PreScission protease added and incubated
overnight. This treatment would be expected to remove the lower band if it was a heat
shock protein, but no effect was observed indicating the lower band was not likely a heat
shock protein.
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A)

B)
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Figure 11: Detection of Np63 using three specific antibodies (4A4, N2C1, H-129)
and confirmation of lower band identity using an anti-GST antibody. A) An aliquot of
recombinant Np63, whole-cell extract from HaCat cells (expressing endogenous
Np63 as a positive control, and GST were incubated with Np63 specific antibodies
and resolved on a 10% SDS-PAGE gel. Coomassie stained Np63 was used as a control,
and whole cell extract from HaCat cells were used as positive control for Np63 Lack
of detection of a lower band using three anti-specific Np63 antibodies indicated that the
lower band is not a degradation fragment of Np63. B) Immunoblot analysis of
recombinant GST, whole-cell extract from HaCaT cells and recombinant Np63using
an anti-GST antibody to demonstrate that the lower band was GST.
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D. Confirmation of Np63 specific binding to peptides to Np63 by Dynabead
assay:
The ability of six biotinylated peptides to bind to Np63 was first examined using
a Dynabead assay system, where the streptavidin beads bind biotinylated peptides.
Immunoblot analysis using p63-specific antibody indicated that binding of Np63 to the
peptide. Figures 12A and 12B show a western blot probed with H-129 antibody for the six
biotinylated peptides bound to Np63 using streptavidin M-280 Dynabeads. Two
different concentrations of each of the selected peptides were incubated with recombinant
Np63. In Figure 12A, loading the beads and Np63 protein as a negative control
resulted in appearance of Np63 band in absence of peptide, indicating nonspecific binding
of Np63 to M-280. In another experiment, no Np63 band was observed in the
negative control (Figure 12B), and biotinylated P5 and P6 showed specific binding to
Np63 compared to M-280 and Np63 alone (Figure 12B). Concerns about nonspecific binding of the M-280 Dynabeads to Np63prompted further analysis with
different Dynabead styles. The manufacturer stated binding capacities are listed in Table
2.
Various streptavidin Dynabeads with low-level non-specific binding to Np63
were tested; M-270, Myone C1 and Myone T1. The six specific biotinylated peptides and
four non-specific biotinylated peptides to Np63 (NE1, NE2, L4, L5) were tested using
M-270. As shown in Figure 13, western blot analysis showed non-specific binding of
Np63 to M270 Dynabeads. Furthermore, three of biotinylated non-specific peptides to
Np63 (NE1, NE2, L5) showed positive binding.
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A)

B)
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Figure 12: Binding of biotinylated peptides to recombinant Np63 using
streptavidin M-280 Dynabeads. A) Either 50 or 100 pmol concentrations of each of four
biotinylated peptides (P1, P2, P3, P4) were incubated with streptavidin M-280 Dynabeads
followed by the addition of recombinant Np63. B) Either 50 or 100 pmol concentrations
of biotinylated peptides (P5, P6) were incubated with streptavidin M-280 Dynabeads
followed by addition of Np63. Np63 alone was used as a positive control.
Streptavidin M-280 Dynabeads alone and in the presence of Np63 were used as negative
controls.
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Table 2: Binding Capacity of four different streptavidin Dynabeads

BEADS
M280
M270
Myone C1
Myone T1

Binding Capacity/ 25 μl beads
50 pmol
50 pmol
100 pmol
100 pmol

P1
P2
P3
P4
P5
P6
pmol
pmol
pmol
pmol
pmol
pmol
50.57
53.8
49.4
54.9
50.9
48.4
50.57
53.8
49.4
54.9
50.9
48.4
101.2
108
98.9
110
102
96.8
101.2
108
98.9
110
102
96.8
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Figure 13: Binding of different concentrations of biotinylated peptides to
recombinant Np63 using streptavidin M-270 Dynabeads. Each biotinylated peptide
(P1, P2, P3, P4, P5, P6) was incubated with streptavidin M-270 Dynabeads followed by
the addition of recombinant Np63 Np63 was used as positive control. Np63 nonspecific biotinylated peptides (NE1, NE2, L4, L5) were used as negative controls.
Streptavidin M-270 Dynabeads alone and in the presence of Np63 were also used as
negative controls.
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The third streptavidin Dynabeads utilized in the binding study was Myone C1.
Western blot analysis using H-129 specific Np63 antibody revealed that there is nonspecific binding of Np63 to Myone C1 Dynabeads (Figure 14A, 14B).
Finally, Myone T1 streptavidin Dynabeads were utilized to examine the binding of
biotinylated peptides to Np63. However, there was also nonspecific binding of Np63
to Myone T1 Dynabeads as shown with other streptavidin Dynabeads (Figure 15).
E. ELISA confirmation of Np63 specific binding to peptides to Np63 by
streptavidin:
Binding affinity of biotinylated peptides to recombinant Np63 was examined
using a streptavidin coated plate approach. An indirect ELISA was performed to identify
the most specific peptide to bind toNp63 (Figure 16). The indirect ELISA utilizes both
a primary antibody (e.g. rabbit anti-p63) and a secondary conjugated antibody (e.g. goatanti-rabbit-HRP) to deliver enhanced sensitivity over the single antibody detection used in
direct ELISAs. In the indirect ELISA, the use of multiple antibodies results in signal
amplification and improved overall assay sensitivity.
Two different Np63 specific antibodies were used. First, polyclonal H-129
antibody was used against Np63. As shown in Figure 17, two concentration of Np63
were incubated with fixed concentration of peptides. The fold increase over Np63 alone
(Y-axis) in presence and absence of peptides is shown. P2 showed a higher fold change
compares to Np63 alone. P3, P5 and P6 showed the highest fold change in presence of
Np63, suggesting that they have the highest affinity to bind to Np63. However, P1
and P4 fold change did not change in presence of both P4 and Np63, suggesting that P4
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had the weakest affinity to bind to Np63. The nonspecific peptide L4 was used as a
negative control which showed no change in fold change in presence of Np63.
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A)

B)
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Figure 14: Binding of biotinylated peptides to recombinant Np63 using
streptavidin Myone C1 Dynabeads. A) Two concentrations of each biotinylated peptides
(P1, P2, P3, P4) were incubated with streptavidin Myone C1 Dynabeads followed by the
addition of recombinant Np63. B) Two concentrations of biotinylated peptides (P5, P6)
were incubated with streptavidin Myone C1 Dynabeads followed by addition of Np63.
Np63 was used as positive control. Streptavidin Myone C1 Dynabeads alone and in the
presence of Np63 were used as negative controls.
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Figure 15: Binding of biotinylated peptides to recombinant Np63 using
streptavidin Myone T1 Dynabeads. Each biotinylated peptide (P1, P2, P3, P4, P5, P6)
was incubated with streptavidin Myone T1 Dynabeads followed by the addition of
recombinant Np63. Np63 was used as positive control. Np63 non-specific
biotinylated peptides (NE1, NE2, L4, L5) were used as negative controls in addition to
Streptavidin Myone T1 Dynabeads alone and in the presence of Np63
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Figure 16: Schematic diagram showing the principle of the indirect ELISA assay.
Biotinylated peptides were incubated in 96 well streptavidin-coated plate overnight. Excess
peptides were washed away, followed by incubation with Np63. Np63 specific
primary antibodies were then added and allowed to incubate for 45 minutes. Next, an HRP
conjugated secondary antibody was added and allowed to incubate for 45 minutes. The
color was developed using TMB and the intensity was read at wavelength 450nm.
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Figure 17: Binding of biotinylated peptides (P1, P2, P3, P4, P5, P6) to Np63 using
a polyclonal antibody (H-129). Graphs display fold-change over Np63 as determined
using ELISA assays with two concentrations (+ = 1.73pmol, ++ = 4.32pmol) of Np63
alone and with 200 pmol biotinylated peptides. The non-specific biotinylated peptide (L4)
was used as negative control. ELISA measurements were performed in triplicate. Error
bars indicate standard deviations. Error bars represent standard deviation between
triplicates. *=p≤0.05 compare to Np63 at 1.73pmol and # =p≤0.05 compare to
Np63 at 4.32pmol. NS= non-significant compare to Np63.
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Finally, we examined the binding of peptides to Np63 utilizing monoclonal antibody
(N2C1). The results (Figure 18) were similar to those obtained using the polyclonal
antibody. P3, P5, P6 and P2 showed high fold change over Np63. Repeated experiments
also indicated that P3, P5 and P6 have the highest affinity to bind to Np63 (data not
shown)
Since the recombinant Np63 sample had residual GST contamination, we tested
if the GST interfered with binding to the biotinylated peptides using an indirect ELISA.
Testing indicated that there was no binding interference from residual GST (Figure 19).
The fold change of GST is shown on the Y-axis, and the data is plotted relative to GST
alone and in presence of peptides (Figure 19). Overall, the ELISA experiments and those
described previously showed that P5 has the highest affinity to bind to Np63. Thus,
further experimentation was completed using biotinylated peptide P5.
A dose dependent study was performed using an ELISA approach to identify the
binding capacity of P5 to bind to Np63. A graph of increasing concentrations of P5 and
constant concentration of Np63 was drawn to identify the binding capacity of P5 to
Np63 as shown in Figure 20A. Biotinylated peptide P5 binding toNp63 was
increased as its concentration increased until reached the saturation at 125 pmol of B-P5.
A dose-dependent assay of Np63 (Figure 20B) indicated that the saturation reached at
2.4 pmol Np63. The dose dependent assay was repeated for each new Np63
preparation. P-value and the fold changes for both antibodies are shown in table 3.
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Figure 18: Binding of biotinylated peptides (P1, P2, P3, P4, P5, P6) to Np63 using
a monoclonal antibody (N2C1). The fold-change over Np63 indicated was determined
by ELISA assay using with two concentrations (+ = 1.73pmol, ++ = 4.32pmol) of Np63
alone and with 200 pmol biotinylated peptides. Non-specific biotinylated peptide (L4) was
used as negative control. Error bars represent standard deviation between triplicates.
*=p≤0.05 compare to Np63 at 1.73pmol and # =p≤0.05 compare to Np63 at
4.32pmol. NS= non-significant compare to Np63.
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Peptide
P1
P2
P3
P4
P5
P6

H-129
N2C1
Fold Change P.value fold Change P.value
1.82
0.001
2.6
0.0003
3.53
0.0003
3.92
2.07E-06
5.72
0.0006
3.13
0.001
1.34
0.004
2.29
0.0004
7.22
7.08E-06
6.83
9.62E-06
5.7
0.0001
5.19
1.68E-05

Table3: fold changes and P.values calculation for six biotinylated peptides.
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Figure 19: Detection of binding of biotinylated peptides (P1, P2, P3, P4, P5, P6) to
GST. The fold-change over GST was determined using an ELISA assay with GST alone
and after incubation with biotinylated peptides. Error bars represent standard deviation
between triplicates. *=p≤0.05 compare to GST at 1.75 pmol. NS= non-significant compare
to GST at 1.75pmol.
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B)
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Figure 20: Dose dependent assay of B-P5 and Np63. A) Fold-change over Np63
alone and in the presence of increasing concentrations of B-P5 display the saturation
concentration of B-P5 to bind to Np63.Error bars represent standard deviation between
triplicates. *=p≤0.05 compare to P5. B) Fold-change over B-P5 alone and in the presence
of increasing concentrations of Np63 showing the saturation concenration
ofNp63Error bars represent standard deviation between triplicates. *=p≤0.05 compare
to Np63
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Finally, we examined the binding of biotinylated P5 to transfected
Np63incells using streptavidin coated plate using ELISA. Figure 21 shows the
fold change over biotinylated peptide P5 (Y-axis) relative to vector transfected cells and
Np63 transfected cells in the presence of biotinylated peptide P5. As expected, an
increase in the fold change of Np63was observed in the presence of B-P5 but not for
empty vector.
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Figure 21: Binding of biotinylated peptides P5 to Np63 compare to empty vector.
Y-axis represents fold change over B-P5 related to Np63 and empty vector in presence
of biotinylated peptides in all cases. Error bars represent standard deviation between
triplicates. *=p≤0.05 compare to empty vector.
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IV.

DISCUSSION

It is well recognized that peptides can serve as receptor agonists, antagonists or
modulators of protein biological function (Smith & Petrenko, 1997). In cancer, many genes
are involved in the tumor growth, making it difficult to identify upstream regulators for a
given gene of interest. Here we utilized phage display technology (Wilson & Finlay, 1998)
to identify upstream modifiers of oncogenic Np63 function. This approach was
performed to focus on the peptide-protein interactions to examine the affinity of specific
peptide(s) which bind to the protein and affect its function. The foundation of this approach
was to prepare pure recombinant Np63 and to utilize peptide phage display technique
to find specific peptide binders.
Many studies have shown the effectiveness of peptides, identified by phage display,
to modulate or regulate protein function. (Shen et al, 2013) used phage display to identify
a peptide which serves as a ligand for prostate-specific membrane antigen (PMSA) in
cancer cells. Another group using phage display to identify a novel peptide called AP8
which is expressed in breast cancer which binds to the acidic fibroblast growth factor
(aFGF) and correlates with disease grade via a direct interaction with fibroblast growth
factor receptors (FGFRs). Functional analysis indicated that AP8 functions as an aFGF
antagonist by preventing aFGF binding to its receptor which inhibits aFGF-stimulated cell
proliferation (Dai et al, 2014).
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In this study, we designed a purification strategy which facilitated the successful
purification of recombinant Np63 sufficient for use in subsequent binding studies. The
method yielded abundant amount of soluble protein, but retained residual GST
contamination.
Our lab previously identified a selection of phage-peptides that bind to the Np63
protein. This project demonstrated the functional binding of these peptides to Np63 and
recombinant Np63. The candidate peptides were synthesized as biotinylated peptides
and in vitro testing using several types of Dynabeads with different binding capacity to
validate binding of these peptides to Np63However, we were unable to confirm the
binding of the peptides to Np63 due to non-specific binding between Np63 and all
styles of Dynabeads tested Manufacturer guidelines suggested that Dynabead size or
concentration may correlate with the degree of non-specific binding (i.e. using smaller
diameter or fewer beads would help to reduce non-specific binding).

Accordingly,

different diameter Dynabeads used in the assay this study, but our data did not support the
contention that smaller beads resulted in lower levels of nonspecific binding. However, a
fixed amount of Dynabeads were used regarding their diameter differences, and it remains
possible that improved results could be obtained by reducing the number of beads used in
the assay. Reduction of nonspecific binding is frequently achieved by adding BSA or
Tween 20 to the reaction mixture per manufacturer recommendations, but both were
ineffective at reducing the non-specific binding (data no shown). It is also possible that
the observed non-specific binding could be overcome by pre-blocking the beads before
Np63 addition. This would serve to reduce nonspecific hydrophobic interactions.
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The Dynabead assay suggested that some of the candidate peptides bound
specifically to Np63, particularly P5 and P6. An alternate streptavidin coated plate
ELISA strategy was performed to clarify the specificity of binding of these peptides to
Np63. The ELISA showed that the P3, P5 and P6 peptides bind to Np63 with higher
affinity than the other peptides. P5 bound to Np63 with the highest affinity, and was
thus selected for further evaluation to test the specificity and the affinity of P5 binding to
Np63
If the peptide binding affinity to Np63 is determined, a recognition site may be
identified which may reveal the specific function of the P5 peptide. It is possible the P5
peptide is involved in targeting Np63 for degradation or may blunt its signaling by
altering the functional confirmation of Np63. The peptide could inhibit protein
oligomerization and retain the protein in an inactive form (Cardinale et al, 2011) in a
manner similar to that observed by the interaction with the oncogenic Head Shock Protein
(gp96). Gp96 binding causes a confirmation change in Np63 which increases binding
to the HER2 receptor and prevents Np63dimerization; thus, the signaling pathway is
terminated leading to the degradation of HER2, decreased cell growth and increased
apoptosis (Li et al, 2015).
Future work will focus on the targeting and internalization of the specific peptide
and thorough an evaluation of the ability of the peptide to modulate the oncogenic effect
of Np63such as examination of the peptide binding affinity to Np63 and an analysis
of the effect of peptide binding to Np63 Further, the activity and affinity of P5 peptide
will be determined using kinetic assays. Finally, the in vivo efficacy of P5 in modulating
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Np63 could be investigated, but testing would require modification of the peptides to
produce cell permeable peptides inhibitors. This study would first reqire that the candidate
peptides be modified to allow cell membrane penetration. One possible modification
includes conjugating the peptides with adapters effective in penetratint the cell membrane
such as those used in the cell penetrating peptides system (CPP). The CPP is proven to
successfully penetrate the cell membrane; however, the ability of the CPP to a target a
linked peptide is not fully elucidated. In addition, another possible modification to allow
cell membrane penetration is by modifying the peptides with membrane-translocating
moieties that increase their hydrophobicity and facilitate cellular entry.
In conclusion, the data presented herein illustrates the effectiveness of phage
display libraries in the search for new peptide based lead structures designed to mimic or
inhibit therapeutically important protein-protein interactions or targeting a specific protein
for degradation.
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